Navigation Links
AIM-Quoted Verona Pharma Progresses Anti-Asthma Drug Studies
Date:11/6/2007

LONDON, November 6 /PRNewswire-FirstCall/ -- AIM-quoted drug discovery company Verona Pharma is pleased to announce another important step forward in the planned development of its anti-asthma and hay fever drug treatment.

The Company's novel anti-asthmatic compound, RPL554, is now entering a second 28-day experimental inhalation toxicology study in another species in order to demonstrate safety, before moving onto the proof of concept clinical trials early next year.

RPL554 is a long-acting bronchodilator/anti-inflammatory molecule being developed to treat hay fever (rhinitis), asthma and chronic obstructive pulmonary disease. A significant feature of RPL554 is that it does not use steroids or beta agonists, which are present in many of today's treatments, but have unwanted side effects and/or limited effectiveness. Verona Pharma is aiming to exploit a major opportunity in the US$20 billion respiratory market with this compound.

RPL554 was invented by Sir David Jack, the former GlaxoSmithKline Research Director who pioneered many of the leading respiratory drugs already in use. Verona Pharma has acquired the intellectual property rights to RPL554 as a key potential new drug within its drug discovery and development portfolio.

The inhalation studies will be undertaken by LAB Research Inc of Hungary, which is already conducting other safety studies on RPL554.

Verona Pharma was admitted to AIM on 19 September 2006. Dr. Walker is Emeritus Professor of Anesthesiology, Pharmacology and Therapeutics at the University of British Columbia, and founder of other biotech and biotech related companies. Chairman Dr. Clive Page is a Professor of Pharmacology at King's College London, and an internationally-recognised authority in lung diseases and inflammation.

Background information follows:

Verona Pharma plc has signed the contract with LAB Research Inc. of Hungary to carry out the second regulatory inhalation toxicity study. The
'/>"/>

SOURCE Verona Pharma PLC
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
5. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014 Barnhardt Manufacturing Company ... its Organic Cotton . The USDA Certified Biobased ... biobased ingredients meets or exceeds levels set by USDA. ... whole or in significant part of agricultural, forestry, or ... Organic cotton to be immediately identified as a USDA ...
(Date:9/19/2014)... , September 19, 2014 , ... European Society for Paediatric Endocrinology (ESPE) Meeting  ... and medical research in the field of growth  , ... Darmstadt, Germany , today announced the ... for 2014. The awards were announced during a Satellite ...
(Date:9/18/2014)... TX (PRWEB) September 18, 2014 ... integrated urological and interventional radiology products and services, ... known as cryotherapy and cryoablation) versus external beam ... Section of the American Urological Association (MAAUA) Annual ... , "Comparing Relative Effectiveness of Cryosurgery and External ...
(Date:9/18/2014)... A novel robotic system that can operate inside ... tested as part of a biomedical research partnership program ... aim of determining if the robot, in conjunction with ... more accurate, less costly, and less discomforting for the ... deliver prostate cancer therapies with greater precision. , Developed ...
Breaking Biology Technology:Barnhardt Manufacturing Company Earns USDA Certified Biobased Product Certification and Label for Organic Cotton 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 4Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 5Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 6
... Telik, Inc.,(Nasdaq: TELK ) announced that the ... partial hold on TELCYTA(R) (canfosfamide HCl, TLK286),clinical trials. ... data by,the agency and permits the resumption of ... Alto, CA is a biopharmaceutical company focused on,discovering, ...
... Show Lower Dose Associated with Fewer Adverse Events in Healthy ... ... ,GlaxoSmithKline,s (NYSE: GSK ) HIV protease inhibitor LEXIVA(R),(fosamprenavir calcium) may now ... level of protease inhibitors in the,bloodstream. The U.S. Food and Drug ...
... Standards, HOFFMAN ESTATES, Ill., Oct. 12 ... which failed quality testing,ConsumerLab.com anonymously purchased, tested and ... CNCA, a leading national distributor,of premium dietary supplements ... health and wellness., "ConsumerLab.com testing showed that ...
Cached Biology Technology:FDA Removes Partial Hold on TELCYTA Clinical Development 2FDA Approves Administration of LEXIVA(R) with Lower Dose of 'Boosting' Medication Ritonavir 2FDA Approves Administration of LEXIVA(R) with Lower Dose of 'Boosting' Medication Ritonavir 3FDA Approves Administration of LEXIVA(R) with Lower Dose of 'Boosting' Medication Ritonavir 4CNCA Exceeds Standards in Nutritional Supplement Quality, Protects Public 2CNCA Exceeds Standards in Nutritional Supplement Quality, Protects Public 3
(Date:9/18/2014)... have built the first smartphone app that automatically ... trends. In other words, your smartphone knows your ... -- and how that affects you. , The ... and loneliness to their academic performance, also may ... example, to monitor mental health, trigger intervention and ...
(Date:9/18/2014)... 18, 2014Many Americans across racial and ethnic groups ... impact on their day-to-day life, more so than ... and speech (57% of African-Americans, 49% of non-Hispanic ... When asked which disease or ailment is the ... first among African-Americans followed by AIDS/HIV. Hispanics ...
(Date:9/18/2014)... several disciplines will be celebrated tonight at the third ... improving the health of premature infants and in paving ... researchers, whose work was supported by the National Science ... Atomic Energy Commission, will be honored at a ceremony ... bipartisan group of Members of Congress will be on ...
Breaking Biology News(10 mins):New Dartmouth smartphone app reveals users' mental health, performance, behavior 2New Dartmouth smartphone app reveals users' mental health, performance, behavior 3New Dartmouth smartphone app reveals users' mental health, performance, behavior 4Americans rate losing eyesight as having greatest impact on their lives 2Americans rate losing eyesight as having greatest impact on their lives 33rd annual Golden Goose award ceremony honors 8 researchers; Unusual work had big results 2
... who initially survive a heart attack, a significant cause of ... literally, bursting of the heart wall. A new ... as the key player in the biochemical cascade that leads ... Advance Online Publication (AOP) of the journal Nature Medicine, ...
... new study, led by PRBO Conservation Science (PRBO), projects a ... sea-level rise scenarios that are increasingly likely. PRBO and ... San Francisco Bay,s tidal marsh could be lost in the ... sea-level rise, low sediment availability and no significant restoration]. ...
... are started in-ground, then sold as bare-root ,liners, to ... To minimize wind damage and to facilitate transport from ... buried deeper than necessary. This deep planting of liners ... important foundations of root systems responsible for trees, health ...
Cached Biology News:Study explains how heart attack can lead to heart rupture 2Study explains how heart attack can lead to heart rupture 3Bleak future for Bay area tidal marshes? 2Bleak future for Bay area tidal marshes? 3Bleak future for Bay area tidal marshes? 4Planting depth's effect on container-grown trees 2